Skip to content
Back to meeting Original
Tomas Pokrivcak, MD, PhD· @pokrivcak · X·· 2 days agoScore45

cabozantinib

Body

Will PAPMET 2 change the guidelines for metastatic papillary RCC?

Cabozantinib remains the preferred option, but IO–TKI combinations look promising.

Tomorrow at #ESMO2026: randomized results of cabozantinib ± atezolizumab.

#PAPMET2 #KidneyCancer

21 views · 0 likes · 0 reposts · 0 replies

Source: Tomas Pokrivcak, MD, PhD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.